IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Company/Organization Date Area of
Collaboration
Terms of Agreement
ProMetic Biosciences 2006 Vaccines Agreement to develop synthetic-ligand
affinity adsorbent for the purification of a
recombinant protein vaccine. ProMetic will
receive funding from Novartis. Financial
details were not disclosed.
Entelos 2006 Drug development Research in multiple disease areas.
Novartis will provide R&D funding, while
Entelos will conduct biosimulation
research, which predicts the effects of
drugs using “virtual patients”. The
technology will provide more information
for Novartis’ drug development, including
the design of phase III clinical trial design.
Financial terms were not disclosed.
Momenta 2006 Biosimilars Agreement between Sandoz and Momenta
to develop four follow-on and complex
generic versions of previously approved
recombinant biotechnology and complex
drugs. Sandoz will make an initial
payment of $75m for the purchase of
approximately 4.7m shares of Momenta,
which is also eligible to receive up to
$188m in additional payments if all
milestones are achieved.
Cytopia 2006 Drug discovery Global license and R&D collaboration to
develop orally active, small molecules
therapeutics targeting JAK3 kinases for
the prevention of transplant rejection and
the treatment of multiple indications in
autoimmune diseases such as rheumatoid
arthritis. Novartis will assume
responsibility for product development and
commercialization. Cytopia has retained
co-promotion rights for Australia and New
Zealand.
Genelabs 2006 Drug discovery Agreement for the development and
commercialization of compounds from
Genelabs’ HCV non-nucleoside drug
discovery program. Genelabs will receive
$20m over a planned two-year research
program. Additional payments could
exceed $175m. In 2008, Genelabs
reported that the partnership was
continuing to the next phase.
© 2009 IMS Health In cor po rated or its af fil i ates Page 132